Surrozen, Inc. (NASDAQ:SRZNW) Sees Large Decrease in Short Interest

Surrozen, Inc. (NASDAQ:SRZNW) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totaling 29,082 shares, a decline of 20.9% from the December 31st total of 36,749 shares. Based on an average daily volume of 1,498 shares, the days-to-cover ratio is presently 19.4 days. Based on an average daily volume of 1,498 shares, the days-to-cover ratio is presently 19.4 days.

Surrozen Price Performance

Shares of NASDAQ SRZNW traded down $0.00 during trading hours on Friday, hitting $0.02. 11,300 shares of the stock were exchanged, compared to its average volume of 4,414. Surrozen has a one year low of $0.00 and a one year high of $0.07. The company’s 50 day moving average is $0.02 and its 200 day moving average is $0.02.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company headquartered in South San Francisco, California, focused on the discovery and development of novel therapeutics that harness the Wnt signaling pathway. The company employs a proprietary “surrogate agonist” platform to engineer bispecific antibodies that mimic natural Wnt ligands by concurrently engaging Frizzled receptors and LRP5/6 co-receptors. This approach is designed to promote tissue regeneration and modulate cellular pathways implicated in fibrosis and oncology.

Surrozen’s lead program is advancing in fibrotic disease, where restoring proper Wnt signaling may support the repair of damaged tissues in conditions such as idiopathic pulmonary fibrosis.